Afimoxifene - CAS 68392-35-8
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Afimoxifene
Catalog Number:
68392-35-8
Synonyms:
4-hydroxytamoxifene; 4-Hydroxytamoxifen ; Hydroxytamoxifen; Tamogel; 4-Hydroxy-tamoxifen ; para-Hydroxytamoxifen ; 4-Monohydroxytamoxifen ; trans-4-Hydroxytamoxifen; Tamoxifen metabolite B ; 4'-hydroxytamoxifen.
CAS Number:
68392-35-8
Description:
Afimoxifene (4-hydroxytamoxifen) is a selective estrogen receptor modulator which is the active metabolite of tamoxifen. Afimoxifene is a transdermal gel formulation and is being developed by Ascend Therapeutics, Inc. under the trademark TamoGel. Afimoxifene has completed a phase II clinical trial for the treatment of cyclical mastalgia.
COA:
Inquire
MSDS:
Inquire
Current Developer:
Ascend Therapeutics, Inc.
Chemical Structure
CAS 68392-35-8 Afimoxifene

Reference Reading


1.Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis.
Hui Y1, Luo L2, Zhang L3, Kurogi K4, Zhou C2, Sakakibara Y4, Suiko M4, Liu MC5. J Pharmacol Sci. 2015 Jul;128(3):144-9. doi: 10.1016/j.jphs.2015.06.004. Epub 2015 Jun 25.
Previous studies demonstrated that sulfate conjugation is involved in the metabolism of three commonly used breast cancer drugs, tamoxifen, raloxifene and fulvestrant. The current study was designed to systematically identify the human cytosolic sulfotransferases (SULTs) that are capable of sulfating raloxifene, fulvestrant, and two active metabolites of tamoxifen, afimoxifene and endoxifen. A systematic analysis using 13 known human SULTs revealed SULT1A1 and SULT1C4 as the major SULTs responsible for the sulfation of afimoxifene, endoxifen, raloxifene and fulvestrant. Kinetic parameters of these two human SULTs in catalyzing the sulfation of these drug compounds were determined. Sulfation of afimoxifene, endoxifen, raloxifene and fulvestrant under metabolic conditions was examined using HepG2 human hepatoma cells and MCF-7 breast cancer cells. Moreover, human intestine, kidney, liver, and lung cytosols were examined to verify the presence of afimoxifene/endoxifen/raloxifene/fulvestrant-sulfating activity.